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Background:The presence of peripheral arterial disease (PAD), even in the absence of overt coronary artery disease (CAD),
confers the same relative risk of death from a cardiovascular cause as in patients with a previous cardiovascular event.
Current guidelines recommend atherosclerotic risk factor–reduction strategies in PAD patients identical to those in
patients with a recent coronary event. The purpose of this study was to determine the status of atherosclerotic risk factor
control in patients with PAD.
Methods: We analyzed the records of patients treated at 2 regional clinics serving 92,940 individuals. Full examination,
laboratory, and pharmacy data were available for all patients. Pharmacy data were analyzed to determine prescriptions for
-blocker therapy, angiotensin-converting enzyme inhibitors, and lipid-lowering agents. Lipid control was assessed
through fasting lipid data. Glycemic control in diabetics was evaluated by using hemoglobin A1c levels.
Results: We administratively identified 2839 patients with a diagnosis of PAD. The exclusion of 1106 patients with a
diagnosis of CAD or validated not to have PAD resulted in a cohort of 1733 patients. Of these, 33.1% (574/1733) were
currently receiving-blockers, 28.9% (500/1733) were receiving an angiotensin-converting enzyme inhibitor, and 31.3%
(543/1733) were receiving a statin. Most patients (92%; 1594/1733) had a recent blood pressure recorded. However,
56% (893/1594) had a systolic blood pressure of 130 mm Hg or higher, 45.5% (726/1594) had a diastolic blood
pressure of 80 mm Hg or higher, and 13.6% (217/1594) had a diastolic blood pressure of 90 mm Hg or higher.
Screening fasting lipid profiles were found in 62.6% (1085/1733) of patients, 56% (508/912) had a low-density
lipoprotein of 100 mg/dL or higher, and 21% (187/912) had a value of more than 130 mg/dL. In patients with diabetes,
a hemoglobin A1c level of 7.0% or higher was found in 54.2% (198/365) of patients.
Conclusions: Despite national consensus of PAD as a CAD equivalent, patients are currently undertreated with regard to
atherosclerotic risk factor modification. Until broader recognition of this disease process exists, vascular surgeons must
continue to champion medical as well as surgical treatments for these patients. ( J Vasc Surg 2005;41:816-22.)Peripheral arterial disease (PAD) is acknowledged to be
a common disease process in elderly patients. Age-adjusted
data from several domestic and European studies suggest
that the prevalence of PAD nears 15% to 20% in patients
older than 65 years.1-6 Patients with PAD incur a 3.1-fold
increase in all-cause mortality over patients without PAD
and a 6.6-fold increased risk of death from coronary artery
disease.7 Only 10% of patients with lower extremity isch-
emia have normal coronary arteries by cardiac catheteriza-
tion, and 28% have severe coronary artery disease.8 Further-
more, the presence of PAD, even in the absence of a history
of coronary artery disease (CAD), confers the same relative
risk of death from a cardiovascular cause as in patients with
a previous cardiovascular event.9,10
Taken together, these data suggest that patients with
PAD should be considered for secondary prevention strat-
egies comparable to those for patients with a previous
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816myocardial infarction (MI). The American Heart Associa-
tion and the National Cholesterol Education Program rec-
ommend identical atherosclerotic risk reduction strategies
for both PAD and CAD patients.11,12 These recommenda-
tions include initiation of -blockade and angiotensin-
converting enzyme inhibitors (ACEi) in all patients, use of
statins to achieve a low-density lipoprotein (LDL) of less
than 100 mg/dL, antiplatelet therapy, and smoking cessa-
tion. The purpose of this study was to determine the status
of atherosclerotic risk factor modification in patients diag-
nosed with PAD.
METHODS
All patients in this study were members of a large,
group-model, not-for-profit managed care system serving
approximately 405,000 patients. Full outpatient medical,
pharmacy, laboratory, and radiology information is stored
in an electronic medical record, allowing for current and
comprehensive analysis.
Patients from 2 large medical offices serving 92,940
patients were administratively screened for a diagnosis of
PAD as defined by (1) an International Classification of
Diseases 9th revision code for claudication or PAD
(443.9), (2) a previous peripheral revascularization proce-
dure, (3) a prescription for either pentoxifylline or cilosta-
zol, (4) an ankle-brachial index (ABI) evaluation or full
noninvasive arterial study, or (5) confirmation by a vascular
surgeon. Patients who were validated not to have PAD
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revascularization procedure) or on determination by a vas-
cular surgeon were excluded. Patients with CAD (as de-
fined by a history of MI, coronary revascularization, coro-
nary catheterization revealing at least 50% stenosis of at
least one vessel, positive thallium stress test with electrocar-
diogram changes indicating ischemia, or unstable angina)
were also excluded.
Centralized computerized pharmacy records for all af-
filiated regional pharmacies were used to identify any pa-
tient in the cohort who picked up at least one prescription
from any of the following classes of medications between
January 1, 2004, and March 31, 2004: -blockers, ACEi,
angiotensin receptor blockers, hydroxymethylglutaryl co-
enzyme A (HMG-CoA) reductase inhibitors (statins), bile
acid sequestrants, fibric acid derivatives, ezetimibe, anti-
platelet agents, or anticoagulants. As members of a man-
aged care organization, most patients have a significant
financial advantage in having their prescriptions filled
through an affiliated pharmacy. Patients are limited to a
60-day supply of medications.
Computerized laboratory records were queried to
identify all patients in the cohort with a fasting lipid profile
between March 1, 2003, and March 31, 2004. Diabetic
patients were identified by cross-referencing the PAD co-
hort with an internal validated diabetes registry. Glycemic
control in this group was evaluated by using hemoglobin
A1c levels during the same interval. The most recent blood
pressure value for each patient was obtained from the
patient’s medical record.
In an effort to ascertain treatment efficacy in this patient
population, we analyzed the number of patients receiving a
lipid-lowering medication with lipid outcomes and antihy-
pertensive medications with blood pressure data. Patients
who had at least one claim for an HMG-CoA reductase
inhibitor during the study period were assigned to the
“statin users” cohort, while those without such a claim
were assigned to the “statin nonusers” cohort. Patients
who had at least one claim for an ACEi, angiotensin recep-
tor blocker, or -blocker were assigned to the “hyperten-
sion medication users” cohort, whereas those without a
such claim were assigned to the “hypertension medication
nonusers” cohort. Patients were categorized as “at goal”
for LDL cholesterol (LDL-C) if their LDL-C reading value
was less than 100 mg/dL. Diabetic patients were catego-
rized as “at goal” for blood pressure if their systolic and
diastolic reading values were less than 130 and 80 mmHg,
respectively. Nondiabetic patients were categorized as “at
goal” for blood pressure if their systolic and diastolic read-
ing values were less than 140 and 90 mm Hg, respectively.
Assessments were made of the distributions of the LDL-C,
total cholesterol, systolic, and diastolic reading values for
each cohort, and it was determined that none was normally
distributed. Thus, to assess the relationship between
LDL-C, total cholesterol, systolic, and diastolic reading
values and medication use, individual nonparametric Wil-
coxon rank sum tests were performed between the cohorts
for each value. To assess the relationship between “at goal”and medication use, individual 2 tests of association were
performed between the cohorts for each goal.
RESULTS
A diagnosis of PAD was identified in 2839 patients out
of 92,940 records examined. The exclusion of 421 patients
confirmed not to have PAD resulted in 2418 patients with
a diagnosis of PAD. Of the 92,940 patients, 15.8% (n 
14,691) were older than 65 years of age, and 56.8% were
female. In the PAD group, 69.7% (n  1685) were more
than 65 years old; thus, the prevalence of PAD in patients
older than 65 years of age was 11.5% (1685/14,691). The
exclusion of 685 patients with a concomitant diagnosis of
CAD and the 421 patients confirmed not to have PAD
resulted in 1733 patients appropriate for this analysis. The
average age of this population was 67.5 years. Amild female
predominance (57.2%) was noted.
Of the 1733 patients, only 33.1% (n  574) were
currently taking a -blocker. Prescriptions for an ACEi
were received by 28.9% (500/1733) of patients, and an
additional 3.6% (62/1733) received an angiotensin recep-
tor blocker. HMG-CoA reductase inhibitors (statins) were
received by 31.3% (543/1733) of patients. Few patients
received bile acid sequestrants (cholestyramine or colesti-
pol; 0.35%; 6/1733), fibrates (gemfibrozil or fenofibrate;
2.0%; 35/1733), or ezetimibe (0.29%; 5/1733).
Aspirin use was not fully recorded in our system be-
cause it is an over-the-counter medication that is not accu-
rately tracked in the pharmacy database. Prescription anti-
platelet therapies were documented in 4.6% of patients
(clopidogrel, n  57; dipyridamole/aspirin, n  23). An-
ticoagulation with warfarin was documented in 257
(14.8%) patients.
Screening lipid profiles were found in 62.6% (1085/
1733) of patients. No lipid profile or cholesterol determi-
nation was performed over the 1-year period in 648 pa-
tients. Average total cholesterol was 195  41.6 mg/dL,
and 42.7% (464/1085) had a total cholesterol of 200
mg/dL or higher. The average LDL was 106  33.4
mg/dL. More than half of the patients who had a lipid
screen (55.7%; 508/912) had an LDL of 100 mg/dL or
higher, and 20.5% (187/912) had a value of more than 130
mg/dL. Average high-density lipoprotein (HDL) was 54
15.9 mg/dL, and only 16.7% (168/1005) had an HDL
level less than 40 mg/dL. Non-HDL cholesterol is used as
a secondary goal in patients with increased triglyceride
levels and reflects the overall atherogenic lipoprotein bur-
den. In our patients, average non-HDL cholesterol was
142  39.7 mg/dL (range, 38-429 mg/dL). More than
half of the population (58.6%; 589/1005) had a non-HDL
cholesterol more than 130mg/dL. Triglyceride levels were
found in 940 patients, with an average of 185 mg/dL, and
52.3% had a value of 150 mg/dL or higher. PAD patients
taking a lipid-lowering agent had significantly lower mean
LDL and total cholesterol levels (Table I) and were more
apt to have reached their target LDL goal (Table II) than
patients not taking a statin.
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414). Most of these patients (88.2%; n  365) had a
documented hemoglobin A1c level. Mean hemoglobin A1c
was 7.41%  1.35%. A hemoglobin A1c level of 7.0% or
higher was found in 54.2% (198/365) of patients. Only
26.3% (96/365) had a value of 8.0% or higher, and 11.2%
(41/365) had a value of 9.0% or higher.
Most patients (92%; 1594/1733) had a recent blood
pressure recorded. However, 56.0% (893/1594) had a
systolic blood pressure of 130mmHg or higher, and 34.1%
(544/1594) had a systolic blood pressure greater than 140
mm Hg. The control of diastolic blood pressure was simi-
lar: 45.5% (726/1594) had a diastolic blood pressure of 80
mmHg or higher, 19.5% (311/1594) had a diastolic blood
pressure of 85 mm Hg or higher, and 13.6% (217/1594)
had a diastolic blood pressure of 90 mm Hg or higher.
Systolic blood pressure was significantly higher in patients
taking antihypertensive medications; this may simply reflect
Table I. Relationships between lipid and blood pressure
values and medication use in PAD patients
Measurement/medication group Mean (n, SD) P value*
LDL-C (mg/dL) .001
Statin users 99.1 (448, 31.4)
Statin nonusers 112.9 (462, 34.1)
Total cholesterol (mg/dL) .001
Statin users 189.4 (476, 37.8)
Statin nonusers 199.8 (607, 43.9)
Systolic blood pressure (mm Hg) .001
HTN medication users† 134.4 (845, 19.5)
HTN medication nonusers 129.2 (747, 17.9)
Diastolic blood pressure (mm Hg) .584
HTN medication users† 76.5 (845, 11.8)
HTN medication nonusers 76.4 (747, 10.0)
PAD, Peripheral arterial disease; LDL-C, low-density lipoprotein choles-
terol; HTN, hypertension.
*Wilcoxon rank sum test.
†Includes angiotensin-converting enzyme inhibitor, angiotensin receptor
blocker, or -blocker.
Table II. Relationships between lipid and blood pressure
goals and medication use in PAD patients
Measurement/medication group % at Goal (n) P value*
LDL-C goal† .001
Statin users 52.0 (448)
Statin nonusers 36.6 (462)
Blood pressure goal‡ .001
HTN medication users§ 49.6 (845)
HTN medication nonusers 64.3 (747)
PAD, Peripheral arterial disease; LDL-C, low-density lipoprotein choles-
terol; HTN, hypertension.
*Chi-square test.
†Goal was LDL-C 100 mg/dL.
‡Goal was 140/90 mm Hg for nondiabetic and 130/80 mm Hg for
diabetic patients.
§Includes angiotensin-converting enzyme inhibitor, angiotensin receptor
blocker, or -blocker.an appropriate diagnosis. Diastolic blood pressure controlwas identical between groups on or off medications (Table
I). Patients taking antihypertensive medications were more
likely to meet their recommended13 blood pressure goal
than those patients not on antihypertensives (Table II).
DISCUSSION
This analysis of unselected patients diagnosed with
PAD by primary care physicians attempts to characterize
the current care of patients with systemic manifestations of
atherosclerosis and the absence of concomitantly diagnosed
CAD. To our knowledge, it is the largest and most detailed
analysis of pharmacologic and laboratory data in this pop-
ulation. Perhaps not surprisingly, we found that patients
with PAD are significantly undertreated and fall well short
of nationally established goals for secondary prevention
(Table III).
Patients’ (and many physicians’) attention is often fo-
cused on resolution of claudication symptoms through
increasingly aggressive revascularization procedures. A
more accurate assessment of threat implicates the heart and
not the leg. The menace of limb threat in patients with
claudication is low,14-16 but their inherent cardiovascular
morbidity and mortality is considerable.7,17,18 This com-
pelling evidence led to the national acceptance of PAD as a
CAD equivalent with broad recommendation for the use of
identical risk reduction strategies in both of these patient
populations.11
Despite these recommendations, physician and patient
recognition of PAD is poor, and its treatment is generally
performed with less attention when compared with patients
with CAD.4,5,19 Reasons for this disparity may include a
simple lack of education, the paucity of focused public
health initiatives, apathy, or inexperience. Vascular medi-
cine is a critical component of vascular surgeons’ education
and practice; however, when compared with other special-
ties, vascular surgeons may be the least likely to initiate
these therapies.4,20
The administration of a -blocker in secondary preven-
tion of a cardiovascular event may decrease mortality by
26% to 39% and is supported by ample level I evidence. In
a retrospective review of 201,752 patients after acute MI,
-blockade was found to reduce mortality by 40% at 2
years.21 Freemantle et al22 performed a meta-analysis of 82
randomized trials encompassing 54,234 patients and con-
firmed a 23% reduction in the odds of death in patients
taking -blockers after MI. It seems to be immaterial which
preparation is used (eg, atenolol, metoprolol, or propran-
olol),23 but it should be continued indefinitely.24 As a
coronary equivalent, all PAD patients should have -block-
ade as part of their medical regimen unless absolutely
contraindicated. There are few data to support the idea that
-blockers may worsen symptoms of claudication, al-
though this has been a historical concern.25,26
Evidence for the use of ACEi in patients with PAD
stems predominantly from theHeart Outcomes Prevention
Evaluation trial, in which 9297 high-risk patients without
ventricular dysfunction were randomized to ramipril or
placebo. In this study, ramipril reduced the risk of cardio-
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Subgroup analyses found that 4051 of the 9297 patients
had a history of PAD, claudication, or an ABI less than 0.9.
This cohort realized a similar benefit from ramipril when
compared with patients without PAD, independent of
ramipril’s effect on blood pressure. The magnitude of this
decrement in cardiovascular risk is equivalent to the benefit
seen in other studies from -blockers, aspirin, or lipid-
lowering agents. ACEi may achieve even greater benefit in
patients with mild congestive heart failure or type 2 diabe-
tes mellitus.28,29
In addition to -blockade and ACE inhibition, strict
control of lipids is well supported as an adjunct in reducing
cardiovascular events after acute MI. A correlation between
serum cholesterol levels and coronary risk was established
through epidemiologic studies.30 Several subsequent large
prospective randomized trials31-34 and a meta-analysis35
have confirmed that statin use results in a 20% to 30%
reduction in cardiovascular and all-cause mortality in pa-
tients with CAD. In our study, 72.5% of patients either had
no cholesterol level checked or had an LDL over the
national target level12 of 100 mg/dL. With recent evidence
suggesting that a greater benefit may be achieved with even
stricter LDL control,36 these data leave great room for
improvement.
Although the intent of aggressive lipid control in pa-
tients with PAD is to reduce cardiovascular complications,
there is evidence that the use of statins may also specifically
limit PAD progression and improve limb function. Mon-
dillo et al37 performed a prospective, randomized, double-
blind trial on the effect of daily simvistatin on walking
performance in 86 patients with PAD. The patients ran-
domized to the statin group achieved a significant improve-
ment in pain-free walking distance, maximal walking dis-
tance, ABI, and claudication symptoms at 6 months. There
is also evidence to suggest that lipid control may limit the
progression of atherosclerosis in peripheral arteries.38-40 It
is interesting to note that McDermott et al41 were able to
document improvements in leg functioning in patients
taking a statin that were independent of the change in
cholesterol levels or the presence or absence of PAD. This
suggests some as-yet-unexplained non–cholesterol-lower-
ing property of these medications.
The Seventh Joint National Committee (JNC 7) on
Prevention, Detection, Evaluation and Treatment of high
blood pressure did not recommend a specific target blood
pressure for patients with isolated CAD or its equivalents13;
however, it did recommend starting treatment for healthy
patients with a systolic blood pressure greater than 140mm
Hg or a diastolic blood pressure greater than 90 mm Hg.
This level of control was not achieved in our PAD popula-
tion in 34% of patients. In patients with diabetes mellitus or
chronic kidney disease, a target blood pressure less than
130/80 mm Hg is recommended.11 No definite first-line
agent is described, but the evidence listed in the preceding
paragraphs strongly supports the use of -blockers and
ACEi.Patients with diabetes incur an increased risk of devel-
oping PAD, and most diabetics die from cardiovascular
disease. Aggressive control of hyperglycemia reduces the
risk of all-cause mortality by 6% in diabetics, but it seems to
affect microvascular disease rather than having any demon-
strable benefit on macrovascular or cardiovascular morbid-
ity.42 National guidelines suggest intensive control of
blood glucose to a target hemoglobin A1c less than 7.0%.
43
Of the 414 patients with diabetes in our study, only 167
(40.3%) had a hemoglobin A1c that was within that goal.
Our study has some limitations, including that we
could not validate the diagnosis of PAD in all of the patients
with noninvasive testing. It is our contention, however,
that patients diagnosed with PAD should be treated as such
unless there is evidence to contradict that diagnosis. In
addition, data regarding tobacco and aspirin use are not
robust in our system but are arguably two of the most
important factors in PAD etiology and treatment.
The data in this study support those of others5,44-46
finding a lack of aggressive risk factor control in patients
with PAD. It is striking that this specific group could
benefit so greatly with what seems to be little more than
improved public and physician education. There seems to
be a somewhat paradoxical physician treatment bias skewed
toward claudication symptom relief rather than essential
risk factor reduction. It is our hope that data such as these
will engender broader use of risk factor–control strategies
that are well established for the secondary prevention of
cardiovascular morbidity.
The authors would like to thank Thomas Delate, PhD,
for his statistical expertise.
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Dr William Pevec, MD (Sacramento, Calif). Based on a large
number of clinical trials, the third report of the National Choles-
terol Education Program published in Circulation in 2002 con-
cluded that peripheral arterial disease whether diagnosed by ABI,
lower limb blood flow studies, or clinical symptoms is a coronary
heart disease equivalent. Patients found to be at risk for coronary
heart disease can benefit from risk-reducing therapies. However,
the 2001 updated guidelines of the American Heart Association
and American College of Cardiology guidelines for preventing
heart attack and death in patients with atherosclerotic cardiovas-
cular disease published in Circulation in 2001 noted that multiple
studies of the actual use of these therapies has shown slow improve-
ment, but continues to show a discouraging conclusion that a large
proportion of patients at risk for cardiovascular disease do not get
the risk-reducing therapies. The report today by Dr Rehring and
his associates confirms that disappointing conclusion. I have sev-
eral questions for the authors.
The authors used relatively soft criteria to define peripheral
arterial disease. I agree with their bias mentioned in the manuscript
that it is better to treat these patients anyway. However, it is
possible that the primary physicians caring for these patients either
did not recognize that these patients had peripheral arterial disease
or were unconvinced by that diagnosis. My question is might this
have been a factor in the relatively low incidence of risk reduction
therapy in the study population?
My second question is medication use was determined as
described in the manuscript by reviewing prescriptions dispensed
by single clinic pharmacy over a three-month period. Could this
result in an underestimation of the use of these drug therapies if
some study subjects had their prescriptions filled at a different
pharmacy or outside this three-month window?
My third question. The authors described a majority of their
patients being women which is counter to the usual distribution of
disease. I am curious if they could comment on that interesting
finding.
The fourth question is the American Heart Association and
American College of Cardiology guidelines are somewhat vague
about the indications for beta blockers in patients without overt
coronary disease, although these guidelines do suggest that ACE
inhibitors be considered in patients with vascular disease. These
medications are clearly indicated in patients with hypertension and
peripheral arterial disease. In this study half the patients had
hypertension, a third were on beta blockers, and a third were on
ACE inhibitors or angiotensin receptor blockers. Did the authors
look at howmany patients with hypertension were on either one of
these drugs and how many patients with hypertension were on
neither of these classes of drugs? This data might give a little more
accurate estimate of the true efficacy of this treatment.
And finally I think the most important question is what should
we do with these data? How should vascular surgeons intervene on
patients with peripheral arterial disease and inadequate risk factor
modification? Should the surgeon prescribe the beta blockers,
ACE inhibitors, insulin and statins? Does this run the risk of toomedications, should the surgeon then be responsible for followup
on the blood pressure, serum glucose and cholesterol profile of
these patients in a serial fashion?
I would like to thank Dr Rehring and his associates for getting
me the manuscript well in advance of the meeting and I would like
to thank the program committee for invitingme to discuss this very
good paper. Thank you.
Dr Thomas F. Rehring (Denver, Colo). The first question
reflected the relatively soft criteria utilized to diagnose peripheral
arterial disease and how that may have impacted risk reduction
treatment by primary care physicians. While utilization of a diag-
nostic code to identify patients in an administrative database is a
fairly standard technique, a lack of conviction by the primary care
provider may certainly be a confounder. It is still our bias however
that if a health care provider labels a patient with a diagnosis of
peripheral arterial disease, they should be treated as such. If the
primary care doctor is unsure of the diagnosis, the patient should
be referred for either a diagnostic study or to a vascular surgeon for
consultation. We captured both of these groups by analyzing
radiology data for results of a noninvasive arterial exam and evalu-
ating all patients with visits to a vascular surgeon.
In response to your second question, all of the patient medi-
cation dispensations are entered in a region-wide, centralized
electronic pharmacy record, so if they fill their prescription at any
pharmacy in the Kaiser system in theDenver, Boulder, or Colorado
Springs area, it would have been captured. These data were ob-
tained over a 90-day period. As prescription refills are limited to 60
days we hoped to capture the vast majority of patients.
We thought the finding of 57% of the cohort being female
interesting as well. When I looked at other large PAD prevalence
studies however, others have noted that it affected the sexes
equally.
With regard to your fourth questionstratification of the anti-
hypertensive data for efficacy is an excellent suggestion and will be
added to the final manuscript.
Your last and obviously the most relevant question is how
should we manage these patients? Is it our job to manage their risk
factors? I wouldn’t presume to tell each surgeon how to manage
their practice as patient flow characteristics can be quite variable
between physicians. I firmly believe it is our job to recommend
these risk-reduction strategies to primary care physicians. The
decision to initiate the therapy for the primary care doctor to follow
must be performed at your own comfort level and on an individual
basis. In my own practice, I have no problem initiating both
antihypertensive therapy (particularly beta blockers) and statin
therapy. This has been welcomed by the primary care doctor.
Dr. Gregory Moneta, MD (Portland, Ore). The Peripheral
Arterial Disease Detection, Awareness and Treatment (PART-
NERS) study indicated a large underdiagnosis of peripheral arterial
disease. My first question would be is there any type of screening
program in place or planned for that diagnosis in your patient
population? And the second one would be that the American
Diabetes Association has actually done analysis of risk factor mod-
ification in patients with diabetes and concluded we weren’t doing
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good job with insulin levels but actually the modification of
cholesterol levels was considerably improved over what it was 10
years ago. So my question would be is there a difference in the use
of these medications in patients who have diabetes or don’t have
diabetes in your population?
Dr Rehring. As you recognized, we do believe PAD is under-
diagnosed, however we have no plans for initiating a screening
program as it would be fairly labor intensive in our population of
over 400,000 patients. We have initiated region-wide CME pro-
grams on PAD.
As to your second question, I do not have data to determine
whether diabetics received better management.
Dr William Krupski, MD (San Francisco, Calif). You men-
tioned statins just briefly. There has been a lot of literature about
use of statins in the coronary patient and to use statins even in the
face of normal lipids. Do you recommend using statins in our
patients even if their lipids are normal and what parameters do you
shoot for now in terms of LDL andHDL levels in view of evidence
that lower is better?
Dr Rehring. There is interesting evidence with several of
these medications that their effect on reductions in cardiovascular
morbidity and mortality are independent of their designed effects.click on “Other SVS Meetings.” mortality independent of their effects on blood pressure and statins
decrease in cardiovascular morbidity and mortality independent of
their effect on cholesterol levels. Statins also improve walking
performance, pain-free walking distance, and claudication symp-
toms independent of their effect on cholesterol. To your point, yes,
I think we should initiate statin therapy in our patients with
peripheral artery disease. As to targeting a lower LDL in this group,
I believe you are referring to a recent study of CAD patients that
suggested that patients with an LDL of 70 had better outcomes
than those with a target of 100. Another study has failed to
duplicate those findings using a separate statin, so I think the jury
is still out. Until more definitive data is available, I continue to
target an LDL of 100.
Dr Anil Hingorani, MD (Brooklyn, NY). How are you
managing your relationship with the primary care physician if you
are starting the patients on beta blockers or statins and are you
following the liver function tests?
Dr Rehring. Yes, that can be an uncomfortable situation. In
some practices and there are primary care doctors who are quite
capable and current in their management of these risk factors.
Others I’ve found will welcome some direction. I think it is our
responsibility to be experts in this area. In my practice, I recom-
mend and initiate therapy and then turn them over to their primaryThat is, ACE inhibitors improve cardiovascular morbidity and care doctor for follow-up. That scheme has been welcomed.
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